Natl Cancer Institute / HIV / AIDS Malignancy Branch — Bethesda, Maryland

Natl Cancer Institute / HIV / AIDS Malignancy Branch is a clinical research site located in Bethesda, Maryland, United States 20892.

Crixeo Clinical Trials Trust Score: 13/100 (FAILING). This profile has not yet been claimed by the site owner.

Natl Cancer Institute / HIV / AIDS Malignancy Branch has participated in 3 clinical trials.

Therapeutic areas: Mycobacterium Avium-intracellulare Infection, HIV Infections, Cytopenias.

Sponsors: Abbott, Sandoz, National Institute of Allergy and Infectious Diseases (NIAID).

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Bethesda

Browse all research sites in Maryland · View every site in Bethesda

Sponsor Feasibility Report

Trust Score: 13/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Natl Cancer Institute / HIV / AIDS Malignancy Branch?

Natl Cancer Institute / HIV / AIDS Malignancy Branch has a Crixeo Trust Score of 13/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Natl Cancer Institute / HIV / AIDS Malignancy Branch conducted?

Natl Cancer Institute / HIV / AIDS Malignancy Branch has 3 clinical trials on record. Their work covers Mycobacterium Avium-intracellulare Infection, HIV Infections, Cytopenias.

Is Natl Cancer Institute / HIV / AIDS Malignancy Branch accredited by Crixeo Clinical Trials?

Natl Cancer Institute / HIV / AIDS Malignancy Branch has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Natl Cancer Institute / HIV / AIDS Malignancy Branch?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.